Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors

Research output: Contribution to journalArticle

Abstract

Human immunodeficiency virus 1 (HIV-1) protease inhibitors are important components of highly active antiretroviral therapy and have had a profound impact on the natural history of HIV and AIDS. However, in the era of highly active antiretroviral therapy (HAART), drug-induced hepatotoxicity or liver injury has emerged as an important potential complication of combination antiretroviral therapy, particularly those regimens containing protease inhibitors (PIs). Liver injury has been associated each of the six PIs currently approved by the U. S. Food and Drug Administration (FDA), most commonly with administration of full dose ritonavir (600 mg bid or 400 mg bid with saquinavir). However, this regimen has been largely replaced by the use of low-dose ritonavir (≤ 200 mg bid) to pharmacologically "boost" other PI, such as lopinavir or indinavir, which has not been associated with an increased risk of hepatotoxicity compared with other PIs. Coinfection with hepatitis C virus (HCV) and B virus (HBV) remains an important risk factor for the development of HAART-associated liver injury. Although studies indicate that coinfected patients can be safely treated with PIs, such patients should be closely monitored. In addition, although unsubstantiated, some experts recommend evaluation or treatment, or both, of underlying chronic viral hepatitis prior to the initiation of anti-retroviral therapy. Further research is needed to understand the etiopathogenesis of PI-associated liver injury, particularly among patients with hepatitis B or C infection.

Original languageEnglish (US)
Pages (from-to)183-193
Number of pages11
JournalSeminars in Liver Disease
Volume23
Issue number2
DOIs
StatePublished - May 2003

Fingerprint

Protease Inhibitors
HIV-1
Highly Active Antiretroviral Therapy
Ritonavir
Liver
Wounds and Injuries
Hepatitis B
Therapeutics
Saquinavir
Lopinavir
Indinavir
Cercopithecine Herpesvirus 1
United States Food and Drug Administration
Chronic Hepatitis
Hepatitis C
Natural History
Coinfection
Hepacivirus
Acquired Immunodeficiency Syndrome
HIV

Keywords

  • HBV
  • HCV
  • Hepatotoxicity
  • HIV
  • Protease inhibitors

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. / Sulkowski, Mark.

In: Seminars in Liver Disease, Vol. 23, No. 2, 05.2003, p. 183-193.

Research output: Contribution to journalArticle

@article{67136fd5d8934b33a0f54fcf6780c279,
title = "Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors",
abstract = "Human immunodeficiency virus 1 (HIV-1) protease inhibitors are important components of highly active antiretroviral therapy and have had a profound impact on the natural history of HIV and AIDS. However, in the era of highly active antiretroviral therapy (HAART), drug-induced hepatotoxicity or liver injury has emerged as an important potential complication of combination antiretroviral therapy, particularly those regimens containing protease inhibitors (PIs). Liver injury has been associated each of the six PIs currently approved by the U. S. Food and Drug Administration (FDA), most commonly with administration of full dose ritonavir (600 mg bid or 400 mg bid with saquinavir). However, this regimen has been largely replaced by the use of low-dose ritonavir (≤ 200 mg bid) to pharmacologically {"}boost{"} other PI, such as lopinavir or indinavir, which has not been associated with an increased risk of hepatotoxicity compared with other PIs. Coinfection with hepatitis C virus (HCV) and B virus (HBV) remains an important risk factor for the development of HAART-associated liver injury. Although studies indicate that coinfected patients can be safely treated with PIs, such patients should be closely monitored. In addition, although unsubstantiated, some experts recommend evaluation or treatment, or both, of underlying chronic viral hepatitis prior to the initiation of anti-retroviral therapy. Further research is needed to understand the etiopathogenesis of PI-associated liver injury, particularly among patients with hepatitis B or C infection.",
keywords = "HBV, HCV, Hepatotoxicity, HIV, Protease inhibitors",
author = "Mark Sulkowski",
year = "2003",
month = "5",
doi = "10.1055/s-2003-39949",
language = "English (US)",
volume = "23",
pages = "183--193",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors

AU - Sulkowski, Mark

PY - 2003/5

Y1 - 2003/5

N2 - Human immunodeficiency virus 1 (HIV-1) protease inhibitors are important components of highly active antiretroviral therapy and have had a profound impact on the natural history of HIV and AIDS. However, in the era of highly active antiretroviral therapy (HAART), drug-induced hepatotoxicity or liver injury has emerged as an important potential complication of combination antiretroviral therapy, particularly those regimens containing protease inhibitors (PIs). Liver injury has been associated each of the six PIs currently approved by the U. S. Food and Drug Administration (FDA), most commonly with administration of full dose ritonavir (600 mg bid or 400 mg bid with saquinavir). However, this regimen has been largely replaced by the use of low-dose ritonavir (≤ 200 mg bid) to pharmacologically "boost" other PI, such as lopinavir or indinavir, which has not been associated with an increased risk of hepatotoxicity compared with other PIs. Coinfection with hepatitis C virus (HCV) and B virus (HBV) remains an important risk factor for the development of HAART-associated liver injury. Although studies indicate that coinfected patients can be safely treated with PIs, such patients should be closely monitored. In addition, although unsubstantiated, some experts recommend evaluation or treatment, or both, of underlying chronic viral hepatitis prior to the initiation of anti-retroviral therapy. Further research is needed to understand the etiopathogenesis of PI-associated liver injury, particularly among patients with hepatitis B or C infection.

AB - Human immunodeficiency virus 1 (HIV-1) protease inhibitors are important components of highly active antiretroviral therapy and have had a profound impact on the natural history of HIV and AIDS. However, in the era of highly active antiretroviral therapy (HAART), drug-induced hepatotoxicity or liver injury has emerged as an important potential complication of combination antiretroviral therapy, particularly those regimens containing protease inhibitors (PIs). Liver injury has been associated each of the six PIs currently approved by the U. S. Food and Drug Administration (FDA), most commonly with administration of full dose ritonavir (600 mg bid or 400 mg bid with saquinavir). However, this regimen has been largely replaced by the use of low-dose ritonavir (≤ 200 mg bid) to pharmacologically "boost" other PI, such as lopinavir or indinavir, which has not been associated with an increased risk of hepatotoxicity compared with other PIs. Coinfection with hepatitis C virus (HCV) and B virus (HBV) remains an important risk factor for the development of HAART-associated liver injury. Although studies indicate that coinfected patients can be safely treated with PIs, such patients should be closely monitored. In addition, although unsubstantiated, some experts recommend evaluation or treatment, or both, of underlying chronic viral hepatitis prior to the initiation of anti-retroviral therapy. Further research is needed to understand the etiopathogenesis of PI-associated liver injury, particularly among patients with hepatitis B or C infection.

KW - HBV

KW - HCV

KW - Hepatotoxicity

KW - HIV

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0038621557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038621557&partnerID=8YFLogxK

U2 - 10.1055/s-2003-39949

DO - 10.1055/s-2003-39949

M3 - Article

C2 - 12800071

AN - SCOPUS:0038621557

VL - 23

SP - 183

EP - 193

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 2

ER -